Skip to main content
. 2017 Jun 6;14(1):499–506. doi: 10.3892/etm.2017.4546

Figure 4.

Figure 4.

Effect of LL-37 treatment and signaling pathway inhibitors on YB-1 protein expression. (A) Effect of 0.05 µg/ml LL-37 treatment for 0, 24, 48 or 72 h on YB-1 protein expression in A431 cells. YB-1 protein levels were determined by western blot analysis. YB-1 protein was measured relative to β-actin protein. (B) Effect of LL-37 treatment (0, 0.05, 0.5 or 5 µg/ml) for 48 h on YB-1 protein expression in A431 cells. YB-1 protein levels were determined by western blot analysis. YB-1 protein was measured relative to β-actin protein. (C) Immunofluorescence assay to evaluate the effect of LL-37 on YB-1 protein levels in A431 cells. A431 cells were stimulated with LL-37 (0, 0.05, 0.5 or 5 µg/ml) for 48 h. Magnification, ×400. (D) Effect of signaling pathway inhibitors on LL-37-induced YB-1 protein expression. A431 cells were pre-treated for 30 min with mitogen-activated protein kinase kinase inhibitor (PD98059, 10 µM), mitogen-activated protein kinase inhibitor (SB203580, 10 µM) or nuclear factor-κB inhibitor (PDTC, 1 µM), followed by treatment with 0.5 µg/ml of LL-37 for 48 h. YB-1 protein levels were determined by western blot analysis. YB-1 protein was measured relative to β-actin protein. *P<0.05 vs. control. YB-1, Y-box binding protein 1; PDTC, ammonium pyrrolidinedithiocarbamate.